The anaemia of silent diabetic nephropathy-prevalence, physiopathology, and management

Acta Clinica Belgica

Volumn 58, Issue 3, 2003, Pages 159-168

  Lameire, Norbert ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDOSTERONE; CYTOKINE; ERYTHROPOIETIN; IRON; RENIN;

ANEMIA; ARTICLE; BELGIUM; BLOOD TRANSFUSION; CLINICAL FEATURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; ERYTHROCYTE ABNORMALITY; GLYCATION; HUMAN; HYPOALDOSTERONISM; HYPORENINEMIA; HYPORENINEMIC HYPOALDOSTERONISM; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA RENIN ACTIVITY;

EID: 0042669744     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2003.58.3.003     Document Type: Article

References (93)

1. Annual Report on management of renal failure in Europe, part 1 ERA-EDTA Registry. 1998. London.
2. van Dijk PC, Jager KJ, de Charro F, Collart F, Cornet R, Dekker FW et al. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant 2001;16(6):1120-29.
3. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34(5):795-808.
4. DOPPS Registry Second wave-preliminary data. 2003.
5. Jungers P, Choukroun G, Robino C, Massy ZA, Taupin P, Labrunie M et al. Epidemiology of end-stage renal disease in the Ile-de-France area: a prospective study in 1998. Nephrol Dial Transplant 2000; 15(12):2000-6.
6. Caramori ML, Mauer M. Diabetes and nephropathy. Curr Opin Nephrol Hypertens 2003; 12(3):273-82.
7. Williams ME. New therapies for advanced glycation end product nephrotoxicity: current challenges. Am J Kidney Dis 2003; 41(3 Suppl 2):S42-S47.
8. Keane WF, Brenner BM, De Zeeuw D, Grunfeld JP, McGill J, Mitch WE et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. Kidney Int 2003; 63(4):1499-507.
9. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH. Diabetic nephropathy. Diabetes Care 2003; 26 Suppl 1:S94-S98.
10. Kikkawa R, Koya D, Haneda M. Progression of diabetic nephropathy. Am J Kidney Dis 2003; 41(3 Suppl 2):S19-S21.
11. Veldman BA, Vervoort G. Pathogenesis of renal microvascular complications in diabetes mellitus. Neth J Med 2002; 60(10):390-6.
12. Brenner BM. Remission of renal disease: recounting the challenge, acquiring the goal. J Clin Invest 2002; 110(12):1753-58.
13. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002; 288(20):2579-88.
14. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162(12):1401-8.
15. Kazmi WH, Kausz AT, Khan S, Abichandani R, Ruthazer R, Obrador GT et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 2001; 38(4):803-812.
16. Harnett JD, Kent GM, Barre PE, Taylor R, Parfrey PS. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol 1994; 4(7):1486-90.
17. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996; 27(3):347-54.
18. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34(1):125-34.
19. London GM, Zins B, Pannier B, Naret C, Berthelot JM, Jacquot C et al. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 1989; 36(5):878-82.
20. Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000; 35(2):250-6.
21. Bedani PL, Verzola A, Bergami M, Stabellini G, Gilli P. Erythropoietin and cardiocirculatory condition in aged patients with chronic renal failure. Nephron 2001; 89(3):350-3.
22. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37(7):1775-80.
23. Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003; 18(1):141-6.
24. Silverberg DS, Wexler D, Blum M, Sheps D, Schwartz D, Yachnin T et al. Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseases. Perit Dial Int 2001; 21 Suppl 3:S236-S240.
25. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28(1):53-61.
26. Madore F, Lowrie EG, Brugnara C, Lew NL, Lazarus JM, Bridges K et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol 1997; 8(12):1921-9.
27. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12(11):2465-73.
28. Sarnak MJ, Tighiouart H, Manjunath G, MacLeod B, Griffith J, Salem D et al. Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 2002; 40(1):27-33.
29. Levin A, Hal W. Prevalence of high risk groups in non-nephrology practices:an international survey. J Am Soc. Nephrol 13, 252A. 2002.
30. Thomas MC, MacIsaac RJ, Tsalamandris C, Power D, Jerums G. Unrecognized anemia in patients with diabetes: a cross-sectional survey. Diabetes Care 2003; 26(4):1164-9.
31. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001; 24(3):495-99.
32. Yun YS, Lee HC, Yoo NC, Song YD, Lim SK, Kim KR et al. Reduced erythropoietin responsiveness to anemia in diabetic patients before advanced diabetic nephropathy. Diabetes Res Clin Pract 1999; 46(3):223-9.
33. Cotroneo P, Maria RB, Todaro L, Pitocco D, Manto A, Ruotolo V et al. Blunted erythropoietin response to anemia in patients with Type 1 diabetes. Diabetes Metab Res Rev 2000; 16(3):172-6.
34. Winkler AS, Marsden J, Chaudhuri KR, Hambley H, Watkins PJ. Erythropoietin depletion and anaemia in diabetes mellitus. Diabet Med 1999; 16(10):813-9.
35. Hadjadj S, Torremocha F, Fanelli A, Brizard A, Bauwens M, Marechaud R. Erythropoietin-dependent anaemia: a possible complication of diabetic neuropathy. Diabetes Metab 2001; 27(3):383-5.
36. Donnelly S, Shah BR. Erythropoietin deficiency in hyporeninemia. Am J Kidney Dis 1999; 33(5):947-53.
37. Levin A. Prevalence of cardiovascular damage in early renal disease. Nephrol Dial Transplant 2001; 16 Suppl 2:7-11.
38. Bosman DR, Osborne CA, Marsden JT, Macdougall IC, Gardner WN, Watkins PJ. Erythropoietin response to hypoxia in patients with diabetic autonomic neuropathy and non-diabetic chronic renal failure. Diabet Med 2002; 19(1):65-9.
39. Gould AB, Goodman S, DeWolf R, Onesti G, Swartz C. Interrelation of the renin system and erythropoietin in rats. J Lab Clin Med 1980; 96(3):523-34.
40. Vlahakos DV, Balodimos C, Papachristopoulos V, Vassilakos P, Hinari E, Vlachojannis JG. Renin-angiotensin system stimulates erythropoietin secretion in chronic hemodialysis patients. Clin Nephrol 1995; 43(1):53-9.
41. Gaston RS, Julian BA, Diethelm AG, Curtis JJ. Effects of enalapril on erythrocytosis after renal transplantation. Ann Intern Med 1991; 115(12):954-5.
42. Conlon PJ, Farrell J, Donohoe J, Walshe JJ. The beneficial effect of enalapril on erythrocytosis after renal transplantation. Transplantation 1993; 56(1):217-9.
43. Koury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 1988; 71(2):524-7.
44. Lacombe C, Da Silva JL, Bruneval P, Fournier JG, Wendling F, Casadevall N et al. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 1988; 81(2):620-3.
45. Piroso E, Erslev AJ, Flaharty KK, Caro J. Erythropoietin life span in rats with hypoplastic and hyperplastic bone marrows. Am J Hematol 1991; 36(2):105-10.
46. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 1988; 242(4884):1412-5.
47. Koury ST, Koury MJ, Bondurant MC, Caro J, Graber SE. Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization: correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. Blood 1989; 74(2):645-51.
48. Zhu H, Jackson T, Bunn HF. Detecting and responding to hypoxia. Nephrol Dial Transplant 2002; 17 Suppl 1:3-7.
49. Lush DJ, King JA, Fray JC. Pathophysiology of low renin syndromes: sites of renal renin secretory impairment and prorenin overexpression. Kidney Int 1993; 43(5):983-99.
50. Inomata S, Itoh M, Imai H, Sato T. Serum levels of erythropoietin as a novel marker reflecting the severity of diabetic nephropathy. Nephron 1997; 75(4):426-30.
51. Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 2002; 17 Suppl 11:39-43.
52. Macdougall IC, Cooper A. The inflammatory response and epoetin sensitivity. Nephrol Dial Transplant 2002; 17 Suppl 1:48-52.
53. Means RT, Jr., Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80(7):1639-47.
54. Dai CH, Price JO, Brunner T, Krantz SB. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. Blood 1998; 91(4):1235-42.
55. Bayes B, Serra A, Junca J, Lauzurica R. Successful treatment of anaemia of nephrotic syndrome with recombinant human erythropoietin. Nephrol Dial Transplant 1998; 13(7):1894-5.
56. Ishimitsu T, Ono H, Sugiyama M, Asakawa H, Oka K, Numabe A et al. Successful erythropoietin treatment for severe anemia in nephrotic syndrome without renal dysfunction. Nephron 1996; 74(3):607-10.
57. Vaziri ND, Kaupke CJ, Barton CH, Gonzales E. Plasma concentration and urinary excretion of erythropoietin in adult nephrotic syndrome. Am J Med 1992; 92(1):35-40.
58. Nowicki M, Kokot F, Kokot M, Bar A, Dulawa J. Renal clearance of endogenous erythropoietin in patients with proteinuria. Int Urol Nephrol 1994; 26(6):691-9.
59. Shuvaev VV, Fujii J, Kawasaki Y, Itoh H, Hamaoka R, Barbier A et al. Glycation of apolipoprotein E impairs its binding to heparin: identification of the major glycation site. Biochim Biophys Acta 1999; 1454(3):296-308.
60. De La Tour DD, Raccah D, Jannot MF, Coste T, Rougerie C, Vague P. Erythrocyte Na/K ATPase activity and diabetes: relationship with C-peptide level. Diabetologia 1998; 41(9):1080-84.
61. Schmid-Schonbein H, Volger E. Red-cell aggregation and red-cell deformability in diabetes. Diabetes 1976; 25(2 SUPPL):897-902.
62. Brown CD, Zhao ZH, De Alvaro F, Chan S, Friedman EA. Correction of erythrocyte deformability defect in ALX-induced diabetic rabbits after treatment with aminoguanidine. Diabetes 1993; 42(4):590-3.
63. Brown CD, Zhao ZH, Thomas LL, Wuert JP, Friedman EA. Pimagedine improves RBC deformability in diabetic patients with ESRD. FASEB J 14, 6A. 2000.
64. Brown CD, Zhao ZH, Thomas LL, deGroof R, Friedman EA. Effects of erythropoietin and aminoguanidine on red blood cell deformability in diabetic azotemic and uremic patients. Am J Kidney Dis 2001; 38(6):1414-20.
65. Nakao T, Matsumoto H, Okada T, Han M, Hidaka H, Yoshino M et al. Influence of erythropoietin treatment on hemoglobin Alc levels in patients with chronic renal failure on hemodialysis. Intern Med 1998; 37(10):826-30.
66. Rigalleau V, Blanchetier V, Aparicio M, Baillet L, Sneed J, Dabadie H et al. Erythropoietin can deteriorate glucose control in uraemic non-insulin-dependent diabetic patients. Diabetes Metab 1998; 24(1):62-5.
67. Foley RN, Culleton BF, Parfrey PS, Harnett JD, Kent GM, Murray DC et al. Cardiac disease in diabetic end-stage renal disease. Diabetologia 1997; 40(11):1307-12.
68. American Diabetes Association. The link between diabetes and cardiovascular disease. 2002.
69. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000; 35(4 Suppl 1):S117-S131.
70. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348(5):383-93.
71. Solomon CG. Reducing cardiovascular risk in type 2 diabetes. N Engl J Med 2003; 348(5):457-9.
72. Shoji T, Emoto M, Shinohara K, Kakiya R, Tsujimoto Y, Kishimoto H et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001; 12(10):2117-124.
73. Qiao Q, Keinanen-Kiukaanniemi S, Laara E. The relationship between hemoglobin levels and diabetic retinopathy. J Clin Epidemiol 1997; 50(2):153-8.
74. Friedman EA, Brown CD, Berman DH. Erythropoietin in diabetic macular edema and renal insufficiency. Am J Kidney Dis 1995; 26(1):202-8.
75. Winkler AS, Watkins PJ. Long-term treatment of the anaemia in Type 1 diabetes mellitus with erythropoietin. Diabet Med 2000; 17(3):250-1.
76. Berman DH, Friedman EA. Partial absorption of hard exudates in patients with diabetic end-stage renal disease and severe anemia after treatment with erythropoietin. Retina 1994; 14(1):1-5.
77. Rarick MU, Espina BM, Colley DT, Chrusoskie A, Gandara S, Feinstein DI. Treatment of a unique anemia in patients with IDDM with epoetin alfa. Diabetes Care 1998; 21(3):423-6.
78. Garcia DL, Anderson S, Rennke HG, Brenner BM. Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci U S A 1988; 85(16):6142-6.
79. Bidani AK, Mitchell KD, Schwartz MM, Navar LG, Lewis EJ. Absence of glomerular injury or nephron loss in a normotensive rat remnant kidney model. Kidney Int 1990; 38(1):28-38.
80. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001; 16(2):307-12.
81. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77(2):176-185.
82. Dikow R, Schwenger V, Schomig M, Ritz E. How should we manage anaemia in patients with diabetes? Nephrol Dial Transplant 2002; 17 Suppl 1:67-72.
83. Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 1996; 50(4):1255-61.
84. Roger SD, Grasty MS, Baker LR, Raine AE. Effects of oxygen breathing and erythropoietin on hypoxic vasodilation in uremic anemia. Kidney Int 1992; 42(4):975-80.
85. Migliori M, Taccola D, Panichi V, De Pietro S, Andreini B, Di Benedetto A et al. Nitric oxide-dependent renal vasodilatation is not altered in rat with rHuEpo-induced hypertension. Kidney Blood Press Res 1999; 22(3):140-5.
86. Gross SS. Vascular biology. Targeted delivery of nitric oxide. Nature 2001; 409(6820):577-8.
87. Zhao G, Zhang X, Smith CJ, Xu X, Ochoa M, Greenhouse D et al. Reduced coronary NO production in conscious dogs after the development of alloxan-induced diabetes. Am J Physiol 1999; 277(1 Pt 2):H268-H278.
88. Ruschitzka FT, Wenger RH, Stallmach T, Quaschning T, de Wit C, Wagner K et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci U S A 2000; 97(21):11609-13.
89. Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13(1):170-6.
90. Kielstein JT, Boger RH, Bode-Boger SM, Schaffer J, Barbey M, Koch KM et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999; 10(3):594-600.
91. Bucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 1995; 26(6):875-88.
92. Berthoux Feal. European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 1999; 14(9 (suppl 5)):11-13.
93. van Ypersele de Strihou C. Should anaemia in subtypes of CRF patients be managed differently? Nephrol Dial Transplant 1999; 14 Suppl 2:37-45.